Health. Reconnected.
You got the drug approved. Now prove it works.
Reimbursement depends on engagement. Engagement depends on behaviour. And right now, nobody can see when someone needs help.
Patients don't disengage overnight. They drift.
Across patient support programmes, post-market follow-up, and clinical trials, the same pattern repeats…
Weeks 1-2
Stable engagement
Regular patterns, consistent activity, routine adherence.
Weeks 3-5
Subtle behavioural shift
Sleep regularity declines. Social contact begins to contract. Phone use fragments.
Weeks 6-8
Drift accelerates
Isolation, routine breakdown, declining adherence. Still invisible to scheduled check-ins.
Week 8+
Formal disengagement
Missed appointments, refill lapses, loss to follow-up. By now, the opportunity to intervene has passed.
40-60%
disengage from PSPs within 6 months
$300bn
annual cost of non-adherence (US)
20-30%
clinical trial dropout before primary endpoint
Two problems. One missing infrastructure layer.
Patient support
Support is reactive and blind
PSPs rely on scheduled nurse calls, self-report questionnaires, and refill data. They detect disengagement after it has happened.
40-60% disengage in 6 monthsReal-world evidence
Effectiveness requires behaviour
Payers and regulators demand evidence of how treatments work outside the trial. But post-market evidence relies on claims and ePRO — missing the continuous behavioural context.
RWE now required for HTASense. Understand. Intervene. Report.
Rumii is a behavioural intelligence platform that gently understands how patients are doing day to day, notices early signs that someone may need support, delivers adaptive interventions, and surfaces operational intelligence — all without requiring anything from the patient.
- 1.
Passive sensing
Smartphone sensor streams (activity, sleep, sociability, routine). Zero patient burden.
- 2.
Behavioural phenotyping
Raw signals become meaningful behavioural patterns — revealing when someone may be struggling, weeks before formal measures would catch it.
- 3.
Adaptive intervention (JITAI)
Compassion-focused behavioural support targeting sleep disruption, routine fragmentation, and social withdrawal. Timed to the patient’s state, not a fixed schedule.
- 4.
Operational intelligence
PSP teams receive behavioural patterns and wellbeing trajectories that highlight who may need support. Additional analytics for payer conversations.
What changes with Rumii?
ADHD medication creates the conditions for behaviour to change — it doesn't deliver the change itself. When the behavioural transition goes unsupported, patients conclude the drug isn't working.
Callum, 23 — diagnosed 6 weeks ago, started on methylphenidate
Works in hospitality · irregular shifts · lives alone · enrolled in PSP · next nurse call in 4 weeks
Week 1
PSP enrolment — initial optimism
Callum starts methylphenidate. Feels a difference immediately — focus is sharper, less impulsive. PSP nurse call confirms good tolerance. Next scheduled contact in 4 weeks. Callum expects the medication to keep doing this on its own.
Week 3
The novelty wears off
The initial “wow” effect fades — pharmacologically normal, but Callum doesn’t know that. Sleep is still chaotic (late shifts, phone until 3am). His routine hasn’t changed. The medication is working neurochemically, but his behaviour hasn’t adapted. Nobody sees this.
Week 4
Callum concludes it isn’t working
Still disorganised. Still late for shifts. Sleep is worse than before diagnosis — now anxious about whether he’s “doing ADHD right.” The gap between expectation and reality feels like proof the drug doesn’t work.
Week 5
Scheduled nurse call — disengaged
Callum says “it’s not really doing much.” The nurse has no behavioural context — no way to know his sleep is fragmented, routine chaotic, expectations misaligned. She documents the feedback. Suggests discussing dose adjustment.
Week 8
Callum stops taking the medication
Doesn’t attend the prescriber appointment. Stops filling the prescription. Disengages from the PSP. Another newly diagnosed patient lost in the first 3 months — not because the medication failed, but because the behavioural transition was unsupported.
Outcome: Patient disengaged
Medication discontinued. PSP lost. No real-world evidence generated. Lifetime treatment relationship potentially compromised at first contact.
Three verticals. One intelligence layer.
Through the Rumii app, JITAI delivers adaptive, compassion-focused support precisely when behavioural signals suggest someone may need it. PSP teams gain real-time wellbeing alerts and cohort-level analytics. Result: more patients staying connected to their treatment, lower cost per supported patient, and continuous real-world evidence generated as a by-product of care.
Rumii adds a continuous behavioural evidence layer that demonstrates real-world treatment impact through behavioural change trajectories. This goes beyond claims data and ePRO to show payers and regulators how treatments actually integrate into patients’ daily lives — sleep, activity, sociability, routine stability.
Real-time insight into how each participant is doing, powered by gentle behavioural sensing. Each day of trial delay costs $800K–$3M. By noticing early signs of struggle, Rumii enables site teams to offer support before a participant drops away — protecting timelines, data integrity, and programme budgets.
Two ways to deploy. One continuous intelligence layer.
Rumii app
Rumii serves 15–30 year olds across conditions — a trusted, branded experience that young people engage with on their own terms. Passive sensing, adaptive support, and operational intelligence for care teams, all within a single consistent product.
Data-as-a-Service
Per-participant, per-year. Phenotypic patterns and behavioural trajectories delivered via API.
SDK integration
Sensing SDK embeds in your existing app. Intelligence delivered via the DaaS layer.
Every programme generates intelligence that makes the next one better
Behavioural phenotypes sharpen with every cohort. Retention prediction models improve across therapeutic areas. Intervention timing and content optimise continuously.
Cross-programme evidence compounds — each new deployment starts from a higher baseline of intelligence. Programme design accelerates. Time-to-value shrinks. Every programme improves the next, because understanding deepens with experience.
Clinical science, not just technology
Clinical psychology at the core
Founded by a clinical psychologist. Every intervention model, every phenotype definition, every alert threshold is grounded in clinical science.
Pharma and CRO operations experience
The team has direct experience in pharma commercial operations, CRO workflows, and PSP programme design.
Pipeline built and operational
Full passive sensing and phenotyping pipeline validated and delivering operational insights. JITAI and intelligence layers are integrated and running in production.
Active research partnerships
Collaborating with academic and clinical partners to validate phenotypic models and intervention efficacy in real populations.